Life SciencesResearch & Development
Instrument data pipelines and the analysis work queued behind them.
Today
With Emerant
What is changing in Life Sciences
The pressures we hear from leadership teams in this sector, and the ones the work below answers.
Validation needs proof
GxP and quality rules require evidence of how each process actually ran.
Long, costly cycles
A delay in trials or submissions is counted in months and millions.
Many reporting audiences
Investors, ESG frameworks and regulators each want a different view of the same data.
Data locked in documents
Lab, finance and regulatory records live in PDFs and spreadsheets.
How we help in Research & Development
The capabilities behind our work here. Open one to see what you get, how to start and the result it moved.
A short, evidence-led engagement that ends with a ranked shortlist, a cost model and an honest list of the things you should not automate yet.
- Start with
- AI Readiness Assessment3 weeks
- Work
- Not yet written up for this sector
Ways to start in Research & Development
Fixed-scope first steps we have run against exactly this kind of problem.
Start here
AI Readiness Assessment
Three weeks to separate the processes where AI changes the economics from the ones where it is an expensive way to run a rule.
- Duration
- 3 weeks
- What you keep
- You leave with a defensible position for the board, built or not.
Lab
Emerging Tech Sprint
Two weeks testing one emerging technology against one of your real processes, ending in a recommendation you can act on or drop.
- Duration
- 2 weeks
- What you keep
- 'Walk away' is a legitimate outcome and we will say it.
Bars drawn to scale: one block is one week.
Our view
Instrument data pipelines and the analysis work queued behind them.
Bring us one process in Research & Development. We will tell you what it would take.
Not a proposal: a straight read on whether it is worth changing, what it costs and where it usually goes wrong in this sector.